STADA, ADCAN Pharma partners to boost UAE pharmaceutical market

UAE—European pharmaceutical company STADA and Abu Dhabi-based ADCAN Pharma have announced a strategic agreement to expand patient access to high-quality medicines in the United Arab Emirates.

This collaboration combines ADCAN’s extensive product development and testing capabilities and local security of supply with STADA’s regional market expertise and strong promotional capabilities across pharmacies, clinics, polyclinics, and hospitals in the Middle East and North Africa (MENA) region.

Notably, ADCAN Pharma boasts an annual production capacity of 500 million tablets and 80 million capsules, meeting all international requirements for pharmaceutical manufacturing.

In the initial phase of the collaboration, which is effective immediately, STADA will exclusively market and commercialize in the UAE a portfolio of 15 high-quality consumer healthcare products produced and supplied by ADCAN.

These include registered skincare and first-aid products such as Dr. Wound Gel and Silvano Spray, as well as several products currently under regulatory review.

These products span various therapeutic categories, including allergy, pain relief, sexual health, vitamins, minerals, and supplements.

 Furthermore, two injectable analgesic formulations that are currently pending regulatory approval in the UAE are included in the agreement.

Stéphane Jacqmin, STADA’s Head of Emerging Markets, expressed his excitement about leveraging STADA’s local marketing and sales strength to bring ADCAN Pharma’s portfolio to more people in the UAE.

He highlighted their admiration for ADCAN’s state-of-the-art Abu Dhabi facility and its product development and stability testing capabilities.

Jacqmin also mentioned that they look forward to exploring opportunities to expand their partnership further.

Commenting on the partnership, Taha Khalidi, ADCAN’s COO/Acting CEO, emphasized the significance of utilizing STADA’s strong market presence to bring their high-quality, locally-manufactured products to a broader audience.

Khalidi noted that this collaboration will support their aspiration to become a leading pharmaceutical industry player in the MENA region.

 He also pointed out that their modern manufacturing site and proximity to the market enable them to make a meaningful contribution to the security of medicine supply in the region.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.